Table 3.

Predictors of overweight/obesity after transplant in recipients with data available on rejection within one yr, by years after transplant and age at transplant^*

6–24 months at transplant			2–6 yr at transplant			2–20 yr at transplant
	OR (95% CI)	p**		OR (95% CI)	p		OR (95% CI)	p
1 yr after transplant (n = 1457)
Underweight at transplant	0.33 (0.16–0.66)	0.002				Underweight at transplant	0.08 (0.01–0.60)	0.014
Overweight/obese at tx	1.87 (1.12–3.13)	0.017	Overweight at transplant	3.29 (1.64–6.57)	0.001	Overweight at transplant	7.80 (4.72–12.9)	<0.001
			Obese at transplant	5.39 (2.60–11.2)	<0.001	Obese at transplant	26.9 (12.1–59.9)	<0.001
Hispanic	1.50 (0.92–2.42)	0.102				Hispanic	1.88 (1.09–3.24)	0.023
						Metabolic liver disease†	0.46 (0.22–0.94)	0.034
						Rejection treated by 1 yr	1.80 (1.20–2.71)	0.005
2 yr after transplant (n = 1104)
Underweight at transplant	0.64 (0.39–1.06)	0.083				Underweight at transplant	0.27 (0.06–1.17)	0.081
Overweight/obese at tx	1.65 (0.93–2.93)	0.086	Overweight at transplant	3.49 (1.61–7.54)	0.001	Overweight at transplant	4.38 (2.48–7.73)	<0.001
			Obese at transplant	5.02 (2.15–11.7)	<0.001	Obese at transplant	13.6 (5.85–31.4)	<0.001
African American	1.50 (0.89–2.55)	0.130				Other ethnicity‡	3.51 (0.94–5.12)	0.061
						Other diagnoses§	2.0 (0.97–4.27)	0.060
5 yr after transplant (n = 445)
Underweight at transplant	0.35 (0.13–0.93)	0.035				Overweight at transplant	2.66 (0.87–8.18)	0.087
						Obese at transplant	31.4 (4.85–203)	<0.001
African American	1.99 (0.89–4.43)	0.093				Female	0.45 (0.19–1.10)	0.080
Other ethnicity	10.2 (0.96–109)	0.054				Hispanic	2.41 (0.82–7.04)	0.108
			Biliary atresia	0.19 (0.02–1.39)	0.102

^*All OR adjusted for age (yr) within age category, gender, race/ethnicity, primary diagnosis (indication for transplant), weight status at transplant, and rejection treated within one yr after transplant. OR compare groups listed to referent groups: male, Caucasian, diagnosis of acute liver failure, normal weight at transplant, no rejection.

^**p-values considered significant if p < 0.05, retained in table for comparison if p < 0.15

^†Metabolic disease includes: alpha-1-antitrypsin deficiency, Crigler–Najjar syndrome, cystic fibrosis, glycogen storage disease, inborn errors in bile acid metabolism, neonatal hemochromatosis, primary hyperoxaluria, tyrosinemia, urea cycle defects, and Wilson’s disease.

^‡Other diagnosis includes: congenital hepatic fibrosis, Budd–Chiari syndrome, autoimmune hepatitis cirrhosis, drug toxicity, hepatitis C cirrhosis, and unknown cirrhosis.

^§Other ethnicity includes: Native American/Alaskan, Pacific Islander/Hawaiian, multiracial, and unknown.